Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Carcinoma, Renal Cell
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Surgical resection is the mainstay of treatment of this disease. Even in patients with disseminated tumor, locoregional forms of therapy may play an important role in palliating symptoms of the primary tumor or of ectopic hormone production. Systemic therapy has demonstrated only limited effectiveness.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Current treatment cures more than 50% of patients with stage I renal cell cancer, but patients with stage IV disease have poor outcomes. All patients with newly diagnosed renal cell cancer are candidates for clinical trials.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for stage I renal cell cancer include:
Radical nephrectomy.[2]
Sources: 2
Simple nephrectomy.[2]
Sources: 2
Cryotherapy.
Thermal ablation.
Stereotactic ablative body radiation therapy (SABR or SBRT) (also referred to as stereotactic radiosurgery).
External-beam radiation therapy (EBRT) (palliative).[2]
Sources: 2
Clinical trials.
Surgical resection is the accepted, often curative therapy for patients with stage I renal cell cancer. In appropriately selected patients, partial nephrectomy has oncologic outcomes that are comparable with those of radical nephrectomy. Partial nephrectomy also has the benefits of preserving greater renal function and, according to some studies, reduced mortality.[4-7] When the entire kidney is removed, resection may be simple or radical. Radical resection includes removal of the kidney, adrenal gland, perirenal fat, and Gerota's fascia, with or without a regional lymph node dissection. Radical nephrectomy is preferred if the tumor extends into the inferior vena cava.
In patients with bilateral stage I neoplasms (concurrent or subsequent), bilateral partial nephrectomy or unilateral partial nephrectomy with contralateral radical nephrectomy, when technically feasible, may be a preferred alternative to bilateral nephrectomy with dialysis or transplant.[1] Increasing evidence suggests that a partial nephrectomy is curative in selected cases. A pathologist should examine the gross specimen as well as the frozen section from the parenchymal margin of excision.[8]
In patients who are not candidates for resection, there are several curative alternatives, including cryoablation, thermal ablation, and SABR (or SBRT).[9-13]
In patients who are not candidates for the treatments above, EBRT or arterial embolization can provide palliation.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for stage II renal cell cancer include:
Partial nephrectomy (selected patients).[1]
Sources: 1
Radical nephrectomy.[1]
Sources: 1
Radical nephrectomy followed by adjuvant pembrolizumab (high-risk patients).[2]
Sources: adjuvant pembrolizumab · 2
Nephrectomy before or after external-beam radiation therapy (EBRT) (selected patients).[1]
Sources: 1
EBRT (palliative).[1]
Sources: 1
Arterial embolization (palliative).
Clinical trials.
Surgical resection is the accepted, often curative, therapy for patients with stage II renal cell cancer. In appropriately selected patients, partial nephrectomy has oncologic outcomes that are comparable with those of radical nephrectomy. Partial nephrectomy also has the benefits of preserving greater renal function and, according to some studies, reduced mortality.[3-6] When the entire kidney is removed, resection may be simple or radical. Radical resection includes removal of the kidney, adrenal gland, perirenal fat, and Gerota's fascia, with or without a regional lymph node dissection. Radical nephrectomy is preferred if the tumor extends into the inferior vena cava. Lymphadenectomy is commonly used, but its effectiveness has not been definitively proven.
Postoperative systemic therapy with the anti-programmed death-1 (PD-1) antibody pembrolizumab has been shown to prolong disease-free survival (DFS), but not overall survival (OS), in patients with high-risk pT2 tumors.
In patients who are not candidates for surgery, arterial embolization can provide palliation.
Adjuvant pembrolizumab
Pembrolizumab is an immune checkpoint inhibitor and a monoclonal antibody targeting the PD-1 protein.
Evidence (adjuvant pembrolizumab):
A double-blind, randomized, placebo-controlled trial (KEYNOTE-564 [NCT03142334]) studied the impact of 1 year of pembrolizumab after nephrectomy. The study enrolled 994 patients with clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. Eligibility included patients with stage II disease with nuclear grade 4 or sarcomatoid differentiation, stage III disease or higher, regional lymph node metastases, or stage M1 status with no evidence of disease after resection. Patients were randomly assigned to receive up to 12 months of pembrolizumab (200 mg) or placebo administered intravenously every 21 days. The primary end point was DFS.[2]Questions have been raised about confounding issues that may have resulted in the significant improvement in DFS in the KEYNOTE-564 trial.[8] An uneven number of patients dropped out in the early follow-up period, which led to a lack of information about recurrence in the control group for the censored patients. Only 36% of the 166 patients in the control group received immunotherapy at relapse, despite conclusive evidence for an OS advantage when immunotherapy is given to patients with metastatic disease. Two other trials using atezolizumab or nivolumab plus ipilimumab failed to show a significant difference in DFS or OS.[9,10] These issues suggest that the U.S. Food and Drug Administration approval of pembrolizumab in the adjuvant setting, and the guidelines released by the National Comprehensive Cancer Network and the European Society for Medical Oncology may have been premature. Further follow-up for more mature DFS and especially OS results is needed.[8,11]
A double-blind, randomized, placebo-controlled trial (KEYNOTE-564 [NCT03142334]) studied the impact of 1 year of pembrolizumab after nephrectomy. The study enrolled 994 patients with clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. Eligibility included patients with stage II disease with nuclear grade 4 or sarcomatoid differentiation, stage III disease or higher, regional lymph node metastases, or stage M1 status with no evidence of disease after resection. Patients were randomly assigned to receive up to 12 months of pembrolizumab (200 mg) or placebo administered intravenously every 21 days. The primary end point was DFS.[2]Questions have been raised about confounding issues that may have resulted in the significant improvement in DFS in the KEYNOTE-564 trial.[8] An uneven number of patients dropped out in the early follow-up period, which led to a lack of information about recurrence in the control group for the censored patients. Only 36% of the 166 patients in the control group received immunotherapy at relapse, despite conclusive evidence for an OS advantage when immunotherapy is given to patients with metastatic disease. Two other trials using atezolizumab or nivolumab plus ipilimumab failed to show a significant difference in DFS or OS.[9,10] These issues suggest that the U.S. Food and Drug Administration approval of pembrolizumab in the adjuvant setting, and the guidelines released by the National Comprehensive Cancer Network and the European Society for Medical Oncology may have been premature. Further follow-up for more mature DFS and especially OS results is needed.[8,11]
At a median follow-up of 24 months, pembrolizumab was associated with a higher 2-year DFS rate than placebo (77.3% for pembrolizumab vs. 68.1% for placebo; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.53–0.87).[2][Level of evidence B1] A subsequent report with a median follow-up of 30 months showed a 75.2% DFS rate for patients who received pembrolizumab, compared with 65.5% for patients who received placebo (HR, 0.63; 95% CI, 0.50–0.80).[7]
Sources: 2 · Level of evidence B1 · 7
Grade 3 or higher adverse events were reported for 32% of patients who received pembrolizumab, and 20% of the patients had serious adverse events. The most common high-grade adverse events were diarrhea and transaminitis, each occurring in 2% of patients who received pembrolizumab. The most common serious adverse events were adrenal insufficiency, colitis, and diabetic ketoacidosis, each occurring in 1% of patients who received pembrolizumab.
OS (the secondary end point) will be assessed when the study has longer follow-up.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for stage III renal cell cancer include:
Radical nephrectomy.[1]
Sources: 1
Radical nephrectomy followed by adjuvant systemic therapy with pembrolizumab or sunitinib.[4,5]
Sources: adjuvant systemic therapy · 4 · 5
External-beam radiation therapy (EBRT) (palliative).[2]
Sources: 2
Tumor embolization (palliative).[3]
Sources: 3
Palliative nephrectomy.
Preoperative or postoperative EBRT and radical nephrectomy.[2]
Sources: 2
Clinical trials involving adjuvant interferon alfa.
Adjuvant systemic therapy
Surgical resection is the standard treatment for patients with clinical stage III renal cell cancer. Several different studies have investigated whether adjuvant (postoperative) systemic therapy improves outcomes. None of these trials have demonstrated any impact on overall survival (OS). However, two agents are associated with longer relapse-free survival.
Adjuvant pembrolizumab
Pembrolizumab is an immune checkpoint inhibitor and a monoclonal antibody targeting the programmed death-1 (PD-1) protein.
Evidence (adjuvant pembrolizumab):
A double-blind, randomized, placebo-controlled trial (KEYNOTE-564 [NCT03142334]) studied the impact of 1 year of pembrolizumab after nephrectomy. The study enrolled 994 patients with clear cell renal cell cancer at high risk of recurrence after nephrectomy. Eligibility included patients with stage II disease with nuclear grade 4 or sarcomatoid differentiation, stage III disease or higher, regional lymph node metastases, or stage M1 status with no evidence of disease after resection. Patients were randomly assigned to receive up to 12 months of pembrolizumab (200 mg) or placebo administered intravenously every 21 days. The primary end point was disease-free survival (DFS).[4]Questions have been raised about confounding issues that may have resulted in the significant improvement in DFS in the KEYNOTE-564 trial.[7] An uneven number of patients dropped out in the early follow-up period, which led to a lack of information about recurrence in the control group for the censored patients. Only 36% of the 166 patients in the control group received immunotherapy at relapse, despite conclusive evidence for an OS advantage when immunotherapy is given to patients with metastatic disease. Two other trials using atezolizumab or nivolumab plus ipilimumab failed to show a significant difference in DFS or OS.[8,9] These issues suggest that the U.S. Food and Drug Administration approval of pembrolizumab in the adjuvant setting, and the guidelines released by the National Comprehensive Cancer Network and the European Society for Medical Oncology may have been premature. Further follow-up for more mature DFS and especially OS results is needed.[7,10]
A double-blind, randomized, placebo-controlled trial (KEYNOTE-564 [NCT03142334]) studied the impact of 1 year of pembrolizumab after nephrectomy. The study enrolled 994 patients with clear cell renal cell cancer at high risk of recurrence after nephrectomy. Eligibility included patients with stage II disease with nuclear grade 4 or sarcomatoid differentiation, stage III disease or higher, regional lymph node metastases, or stage M1 status with no evidence of disease after resection. Patients were randomly assigned to receive up to 12 months of pembrolizumab (200 mg) or placebo administered intravenously every 21 days. The primary end point was disease-free survival (DFS).[4]Questions have been raised about confounding issues that may have resulted in the significant improvement in DFS in the KEYNOTE-564 trial.[7] An uneven number of patients dropped out in the early follow-up period, which led to a lack of information about recurrence in the control group for the censored patients. Only 36% of the 166 patients in the control group received immunotherapy at relapse, despite conclusive evidence for an OS advantage when immunotherapy is given to patients with metastatic disease. Two other trials using atezolizumab or nivolumab plus ipilimumab failed to show a significant difference in DFS or OS.[8,9] These issues suggest that the U.S. Food and Drug Administration approval of pembrolizumab in the adjuvant setting, and the guidelines released by the National Comprehensive Cancer Network and the European Society for Medical Oncology may have been premature. Further follow-up for more mature DFS and especially OS results is needed.[7,10]
At a median follow-up of 24 months, pembrolizumab was associated with a higher 2-year DFS rate than placebo (77.3% for pembrolizumab vs. 68.1% for placebo; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.53–0.87).[4][Level of evidence B1] A subsequent report with a median follow-up of 30 months showed a 75.2% DFS rate for patients who received pembrolizumab, compared with 65.5% for patients who received placebo (HR, 0.63; 95% CI, 0.50–0.80).[6]
Sources: 4 · Level of evidence B1 · 6
Grade 3 or higher adverse events were reported for 32% of patients who received pembrolizumab, and 20% of the patients had serious adverse events. The most common high-grade adverse events were diarrhea and transaminitis, each occurring in 2% of patients who received pembrolizumab. The most common serious adverse events were adrenal insufficiency, colitis, and diabetic ketoacidosis, each occurring in 1% of patients who received pembrolizumab.
OS (the secondary end point) will be assessed when the study has longer follow-up.
Adjuvant sunitinib
Sunitinib is an oral tyrosine kinase inhibitor targeting the vascular endothelial growth factor pathway.
Evidence (sunitinib):
A double-blind, placebo-controlled, randomized trial (NCT00375674) studied the impact of sunitinib after nephrectomy in patients with locoregional, high-risk, clear cell renal cell cancer (stage T3 or higher and/or regional lymph node metastases). The study randomly assigned 615 patients to receive either 1 year of sunitinib (50 mg) or placebo once daily for the first 4 weeks of a repeating 6-week cycle (i.e., a 4-week-on, 2-week-off schedule).[5]
Sources: NCT00375674 · 5
A double-blind, placebo-controlled, randomized trial (NCT00375674) studied the impact of sunitinib after nephrectomy in patients with locoregional, high-risk, clear cell renal cell cancer (stage T3 or higher and/or regional lymph node metastases). The study randomly assigned 615 patients to receive either 1 year of sunitinib (50 mg) or placebo once daily for the first 4 weeks of a repeating 6-week cycle (i.e., a 4-week-on, 2-week-off schedule).[5]
The median DFS was 6.8 years for patients who received sunitinib and 5.6 years for patients who received placebo (HR, 0.76; 95% CI, 0.59–0.98; P = .03). No difference in OS was reported (HR, 1.01; 95% CI, 0.72–1.44; P = .94).
Dose reductions were reported in 34% of patients who received sunitinib. Dose interruptions were seen in 46% of patients, and 28% of patients assigned to sunitinib discontinued the medication.
Of patients who received sunitinib, 48% experienced grade 3 adverse events and 12% experienced grade 4 adverse events. The most common high-grade adverse events were palmar-plantar erythrodysesthesia, hypertension, fatigue, neutropenia, thrombocytopenia, and mucosal inflammation.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Radical resection is the accepted, often curative therapy for patients with this stage of renal cell cancer. The operation includes removal of the kidney, adrenal gland, perirenal fat, and Gerota's fascia, with or without a regional lymph node dissection.[11] Lymphadenectomy is commonly used, but its effectiveness has not been definitively proven. EBRT has been given before or after nephrectomy, without conclusive evidence that it improves survival compared with the results of surgery alone. However, it may benefit selected patients with more extensive tumors.
Sources: 11
In patients with bilateral stage T3a neoplasms (concurrent or subsequent), bilateral partial nephrectomy or unilateral partial nephrectomy with contralateral radical nephrectomy, when technically feasible, may be a preferred alternative to bilateral nephrectomy with dialysis or transplant.[12]
Sources: 12
In patients who are not candidates for surgery, arterial embolization can provide palliation.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Radical resection is the accepted, often curative therapy for patients with this stage of renal cell cancer. The operation includes removal of the kidney, adrenal gland, perirenal fat, and Gerota's fascia, with or without a regional lymph node dissection.[11] Lymphadenectomy is commonly used, but its effectiveness has not been definitively proven. Surgery is extended to remove the entire renal vein and caval thrombus and a portion of the vena cava as necessary.[1] EBRT has been given before or after nephrectomy, without conclusive evidence that it improves survival compared with the results of surgery alone. However, it may benefit selected patients with more extensive tumors.
In patients with stage T3b neoplasms who manifest concurrent or subsequent renal cell cancer in the contralateral kidney, a partial nephrectomy, when technically feasible, may be a preferred alternative to bilateral nephrectomy with dialysis or transplant.[12-14]
In patients who are not candidates for surgery, arterial embolization can provide palliation.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
This stage of renal cell cancer is curable with surgery in a small minority of patients. A radical nephrectomy and lymph node dissection is necessary. The value of preoperative and postoperative EBRT has not been demonstrated, but EBRT may be used for palliation in patients who are not candidates for surgery. Arterial embolization of the tumor with Gelfoam or other materials may be used preoperatively to reduce blood loss at nephrectomy or for palliation in patients with inoperable disease.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for first-line therapy for stage IV renal cell cancer include:
Ipilimumab plus nivolumab (for patients with intermediate or poor-risk disease).[1]
Sources: Ipilimumab plus nivolumab · 1
Pembrolizumab plus axitinib.[2]
Sources: Pembrolizumab plus axitinib · 2
Pembrolizumab plus lenvatinib.[3]
Sources: Pembrolizumab plus lenvatinib · 3
Nivolumab plus cabozantinib.[4]
Sources: Nivolumab plus cabozantinib · 4
Radical nephrectomy (for T4, M0 lesions).
Cytoreductive nephrectomy (for any T, M1 lesions in patients with good-risk disease).[5-8]
Sources: Cytoreductive nephrectomy · 5 · 8
Cabozantinib (for patients with intermediate- or poor-risk disease).[9,10]
Sources: Cabozantinib · 9 · 10
Avelumab plus axitinib.[11]
Sources: Avelumab plus axitinib · 11
Interferon alfa.[16-19]
Sources: Interferon alfa · 16 · 19
Interleukin-2 (IL-2).[16,20,21]
Sources: Interleukin-2 · 16 · 20 · 21
Palliative external-beam radiation therapy (EBRT).
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for second-line therapy for stage IV renal cell cancer include:
Nivolumab (for patients previously treated with sunitinib, pazopanib, sorafenib, and/or axitinib).[22]
Lenvatinib plus everolimus (for patients previously treated with sunitinib, pazopanib, cabozantinib, axitinib, or sorafenib).[23]
Sources: Lenvatinib plus everolimus · 23
Cabozantinib (for patients previously treated with sunitinib, pazopanib, sorafenib, or axitinib).[24]
Sources: Cabozantinib · 24
Belzutifan.[25]
Sources: Belzutifan · 25
Palliative EBRT.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for third- and fourth-line therapy for stage IV renal cell cancer include:
Temsirolimus.[31]
Sources: Temsirolimus · 31
Everolimus (for patients previously treated with sunitinib and/or sorafenib).[37]
Sources: Everolimus · 37
Any of the agents listed for first- or second-line therapy.
The prognosis is poor for any patient with renal cell cancer that is progressing, recurring, or relapsing after treatment, regardless of cancer cell type or stage of disease. Almost all patients with stage IV renal cell cancer have incurable disease. The use and selection of further treatment depends on many factors, including previous treatment and site of recurrence, as well as individual patient considerations. Carefully selected patients may benefit from surgical resection of localized metastatic disease, particularly if they have had a prolonged disease-free interval since their primary therapy.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Immune checkpoint inhibitors are drugs that block certain proteins that inhibit the immune system's response to cancer. These proteins down-regulate T-lymphocyte activity and can prevent these cells from killing cancer cells. By reducing the activity of these inhibitory proteins, immune checkpoint inhibitors increase the immune response to cancer. Immune checkpoint proteins that are targeted by this class of drugs include programmed death-1 (PD-1), programmed cell death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
In a randomized controlled trial, the combination of ipilimumab and nivolumab prolonged overall survival (OS) when compared with sunitinib as first-line systemic therapy for patients with advanced-stage renal cell carcinoma.[1] Both drugs are immune checkpoint inhibitors. Ipilimumab is an antibody that targets CTLA-4. Nivolumab is an antibody that targets PD-1.
Sources: 1
Evidence (ipilimumab plus nivolumab):
A randomized controlled trial compared the combination of ipilimumab and nivolumab with sunitinib. Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) were given every 3 weeks for four doses, followed by maintenance nivolumab (3 mg/kg) every 2 weeks. Sunitinib was given at a dose of 50 mg once daily for the first 4 weeks of a repeating 6-week cycle (i.e., each cycle consisted of 4 weeks taking the drug, followed by a 2-week break). Treatment continued until disease progression unless adverse events or withdrawal of consent led to discontinuation. The coprimary end points were OS, progression-free survival (PFS), and objective response rate in patients with intermediate- or poor-risk disease. Of note, because there were three primary end points, the overall alpha level of 0.05 was divided among the three end points. This meant that the P-value cutoffs for significance were 0.001 for response rate, 0.009 for PFS, and 0.04 for OS. The trial enrolled 1,096 patients, 847 of whom had intermediate- or poor-risk disease.
A randomized controlled trial compared the combination of ipilimumab and nivolumab with sunitinib. Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) were given every 3 weeks for four doses, followed by maintenance nivolumab (3 mg/kg) every 2 weeks. Sunitinib was given at a dose of 50 mg once daily for the first 4 weeks of a repeating 6-week cycle (i.e., each cycle consisted of 4 weeks taking the drug, followed by a 2-week break). Treatment continued until disease progression unless adverse events or withdrawal of consent led to discontinuation. The coprimary end points were OS, progression-free survival (PFS), and objective response rate in patients with intermediate- or poor-risk disease. Of note, because there were three primary end points, the overall alpha level of 0.05 was divided among the three end points. This meant that the P-value cutoffs for significance were 0.001 for response rate, 0.009 for PFS, and 0.04 for OS. The trial enrolled 1,096 patients, 847 of whom had intermediate- or poor-risk disease.
With a median follow-up of 25.2 months for intermediate- and poor-risk patients, the 18-month OS rate was 75% in the ipilimumab-plus-nivolumab arm, compared with 60% in the sunitinib arm. Among patients with intermediate- and poor-risk disease, the hazard ratio (HR)death was 0.63 (99.8% confidence interval [CI], 0.44–0.89; P < .001).
There was no statistically significant difference in PFS. Median PFS among patients with intermediate- and poor-risk disease was 11.6 months with ipilimumab plus nivolumab, compared with 8.4 months with sunitinib (HR, 0.82; 99.1% CI, 0.64–1.05).
The objective response rate was higher with ipilimumab plus nivolumab than with sunitinib (42% vs. 27%, P < .001). In the ipilimumab-plus-nivolumab arm, 40 patients (9%) had complete responses, compared with 5 patients (1%) in the sunitinib arm.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Nivolumab is the only treatment that has shown prolonged OS in patients who have previously received antiangiogenic therapy. Nivolumab is a fully human antibody that blocks ligand activation of the PD-1 protein. By blocking the interaction between PD-1 and PD-1 ligands 1 and 2, nivolumab blocks a pathway that inhibits the cellular immune response and restores cellular immunity.
Evidence (nivolumab):
A phase II trial showed promising results and no dose response with nivolumab, which was given every 3 weeks at a dose of 0.3 mg/kg, 2 mg/kg, or 10 mg/kg.[22]
Sources: 22
A phase II trial showed promising results and no dose response with nivolumab, which was given every 3 weeks at a dose of 0.3 mg/kg, 2 mg/kg, or 10 mg/kg.[22]
The median survival was 25.5 months with a dose of 2 mg/kg given every 3 weeks and 24.7 months with a dose of 10 mg/kg given every 3 weeks.
A randomized controlled trial compared nivolumab at a dose of 3 mg/kg every 2 weeks with everolimus at a dose of 10 mg daily.[38] The trial randomly assigned 821 patients with metastatic renal cell cancer and a clear cell component who had previously received one or two antiangiogenic regimens. It is not clear whether the dose of 3 mg/kg every 2 weeks used in the phase III trial offers any advantage over the dose of 2 mg/kg every 3 weeks used in the phase II trial. However, the latter dose offers substantial cost savings.
Sources: 38
A randomized controlled trial compared nivolumab at a dose of 3 mg/kg every 2 weeks with everolimus at a dose of 10 mg daily.[38] The trial randomly assigned 821 patients with metastatic renal cell cancer and a clear cell component who had previously received one or two antiangiogenic regimens. It is not clear whether the dose of 3 mg/kg every 2 weeks used in the phase III trial offers any advantage over the dose of 2 mg/kg every 3 weeks used in the phase II trial. However, the latter dose offers substantial cost savings.
The objective response rate was 25% with nivolumab, compared with 5% with everolimus (P < .001).
The median duration of treatment was 5.5 months with nivolumab, compared with 3.7 months with everolimus, and there was no significant difference in PFS (median PFS, 4.6 months with nivolumab vs. 4.4 months with everolimus).
However, OS was significantly longer with nivolumab (median OS, 25.0 months vs. 19.6 months; HR, 0.73; 98.5% CI, 0.57–0.93).[38]
Sources: 38
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Cytokine therapy with interferon alfa or IL-2 has been shown to induce objective responses. Interferon alfa appears to have a modest impact on survival in selected patients. Interferon alfa has approximately a 15% objective response rate in appropriately selected individuals.[16] In general, these patients have nonbulky pulmonary or soft tissue metastases with excellent performance status ratings of 0 or 1, according to the Eastern Cooperative Oncology Group (ECOG) rating scale, and the patients show no weight loss. The interferon alfa doses used in studies reporting good response rates have been in an intermediate range (6–20 million units administered 3 times weekly). A Cochrane analysis of six randomized trials, with a total of 963 patients, indicated an HR for survival of 0.78 (0.67–0.90) or a weighted average improvement in survival of 2.6 months.[16][Level of evidence A1]
Sources: 16 · 16 · Level of evidence A1
High-dose IL-2 produces an overall response rate similar to that of interferon alfa, but approximately 5% of the patients have shown durable complete remissions.[20,39-43] No randomized controlled trial of IL-2 has shown a longer survival result. High-dose IL-2 is used because it is the only systemic therapy that has been associated with inducing durable complete remissions, albeit in a small fraction (about 5%) of patients who are eligible for this treatment. The optimum dose of IL-2 is unknown. High-dose therapy appears to be associated with higher response rates but with more toxic effects. Low-dose inpatient regimens show activity against renal cell carcinoma with fewer toxic effects, especially hypotension, but have not been shown to be superior to placebo or any alternative regimen in terms of survival or quality of life (QOL).[21] Outpatient subcutaneous administration has also demonstrated responses with acceptable toxic effects but, again, with unclear survival or QOL benefit.[44] Combinations of IL-2 and interferon alfa have been studied, but outcomes have not been better than with high-dose or low-dose IL-2 alone.[17,45]
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
After immune checkpoint inhibitors and antiangiogenic targeted therapies were found to improve outcomes, clinical trials of the combination of these two approaches showed longer OS when compared with monotherapy.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (pembrolizumab plus axitinib):
An open-label, phase III, randomized controlled trial (NCT02853331) compared sunitinib with the combination of pembrolizumab and axitinib. The study enrolled 861 patients who had received no previous systemic therapy for metastatic disease.[2]
Sources: NCT02853331 · 2
An open-label, phase III, randomized controlled trial (NCT02853331) compared sunitinib with the combination of pembrolizumab and axitinib. The study enrolled 861 patients who had received no previous systemic therapy for metastatic disease.[2]
With median follow-up of 12.8 months, the 1-year OS rate was 90% in the pembrolizumab-plus-axitinib arm, compared with 78% in the sunitinib arm (HR, 0.53; 95% CI, 0.38–0.74; P < .0001).[2][Level of evidence A1]
Sources: 2 · Level of evidence A1
Median PFS was also prolonged for patients who received the combination therapy (15.1 months vs. 11.1 months; HR, 0.69; 95% CI, 0.57–0.84).
The objective response rate was 59.3% for patients who received combination therapy, compared with 35.7% for patients who received sunitinib (P < .001).
Grade 3 or higher adverse event rates were similar: 75.8% of the patients in the pembrolizumab-plus-axitinib arm, compared with 70.6% of the patients in the sunitinib arm.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (pembrolizumab plus lenvatinib):
An open-label, phase III, randomized controlled trial (NCT02811861) compared sunitinib with either lenvatinib plus pembrolizumab or lenvatinib plus everolimus. The study enrolled 1,609 patients who had received no previous systemic therapy for metastatic disease.[3]
Sources: NCT02811861 · 3
An open-label, phase III, randomized controlled trial (NCT02811861) compared sunitinib with either lenvatinib plus pembrolizumab or lenvatinib plus everolimus. The study enrolled 1,609 patients who had received no previous systemic therapy for metastatic disease.[3]
With a median follow-up of 26.6 months, the 2-year OS rate was 79.2% in the pembrolizumab-plus-lenvatinib arm, compared with 70.4% in the sunitinib arm (HR, 0.66; 95% CI, 0.49–0.88; P = .005).[3][Level of evidence A1] There was no difference in OS between the sunitinib and lenvatinib-plus-everolimus arms.
Sources: 3 · Level of evidence A1
The median PFS was also longer with pembrolizumab plus lenvatinib than with sunitinib (23.9 months vs. 9.2 months; HR, 0.39; 95% CI, 0.32–0.49; P < .001). The PFS was also longer in the lenvatinib-plus-everolimus arm (14.7 months), compared with the sunitinib arm (HR, 0.65; 95% CI, 0.53–0.80; P < .001).
The objective response rate was 71.0% with pembrolizumab-plus-lenvatinib therapy, compared with 36.1% with sunitinib (P < .001). Complete responses were reported in 16.1% of patients in the pembrolizumab-plus-lenvatinib arm, 4.2% of patients in the sunitinib arm, and 9.8% of patients in the lenvatinib-plus-everolimus arm.
Grade 3 or higher adverse event rates were more common in the lenvatinib arms: 82.4% of the patients in the pembrolizumab-plus-lenvatinib arm and 83.1% of patients in the lenvatinib-plus-everolimus arm, compared with 71.8% of patients in the sunitinib arm. Treatment was discontinued in 37.2% of patients in the pembrolizumab-plus-lenvatinib arm, compared with 14.4% of patients in the sunitinib arm. Hypertension (27.6%), diarrhea (9.7%), and weight loss (8.0%) were the most common high-grade toxicities in the pembrolizumab-plus-lenvatinib arm.
Health-related quality of life (HRQOL) was assessed using multiple measures. The results showed that patients who received pembrolizumab and lenvatinib had similar or less deterioration of their HRQOL and disease-related symptom scores over time when compared with patients who received sunitinib.[46][Level of evidence B2]
Sources: 46 · Level of evidence B2
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (nivolumab plus cabozantinib):
An open-label, phase III, randomized controlled trial (NCT03141177) compared sunitinib with nivolumab plus cabozantinib. The study enrolled 651 patients who had received no previous systemic therapy for metastatic disease.[47]
Sources: NCT03141177 · 47
An open-label, phase III, randomized controlled trial (NCT03141177) compared sunitinib with nivolumab plus cabozantinib. The study enrolled 651 patients who had received no previous systemic therapy for metastatic disease.[47]
With a median follow-up of 32.9 months, the OS was 37.7 months in the nivolumab-plus-cabozantinib arm, compared with 34.3 months in the sunitinib arm (HR, 0.70; 95% CI, 0.55–0.90).[47][Level of evidence A1]
Sources: 47 · Level of evidence A1
The median PFS was also longer in the nivolumab-plus-cabozantinib arm than in the sunitinib arm (16.6 months vs. 8.3 months; HR, 0.51; 95% CI, 0.41–0.64; P < .001).
The objective response rate was 55.7% for patients who received combination therapy, compared with 27.1% for patients who received sunitinib (P < .001).
Grade 3 or higher adverse event rates were reported in 65% of patients who received nivolumab plus cabozantinib, compared with 54% of those who received sunitinib. High-grade treatment-related serious adverse events were reported in 22% of patients in the combination therapy arm and 10% of patients in the sunitinib arm. At least one of the trial drugs was discontinued in 19.7% of those assigned to combination therapy, compared with 16.9% of those assigned to sunitinib. The most common high-grade toxicities with combination therapy were hypertension (12.5%), hyponatremia (9.4%), diarrhea (6.9%), elevated lipase (6.2%), and hypophosphatemia (5.9%).
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Evidence (avelumab plus axitinib):
An open-label, phase III, randomized trial (NCT02684006) compared the combination of avelumab and axitinib with sunitinib monotherapy. The study included 560 patients with previously untreated stage IV PD-L1–positive renal cell carcinoma (the entire study population was 886 patients, including those who were PD-L1 negative).[11] This trial specified two primary end points: PFS and OS among patients with PD-L1-positive tumors. PFS among the entire study population was a secondary end point.
Sources: NCT02684006 · 11
An open-label, phase III, randomized trial (NCT02684006) compared the combination of avelumab and axitinib with sunitinib monotherapy. The study included 560 patients with previously untreated stage IV PD-L1–positive renal cell carcinoma (the entire study population was 886 patients, including those who were PD-L1 negative).[11] This trial specified two primary end points: PFS and OS among patients with PD-L1-positive tumors. PFS among the entire study population was a secondary end point.
With a median follow-up of less than 1 year, there was no significant difference in OS between the two arms.
Among patients with PD-L1–positive tumors, the PFS was 13.8 months in the combination therapy arm, compared with 7.2 months in the sunitinib arm (HR, 0.61; 95% CI, 0.47–0.79).[11][Level of evidence B1]
Sources: 11 · Level of evidence B1
For the entire study population, the median PFS was 13.8 months in the combination arm, compared with 8.4 months in the sunitinib arm (HR, 0.69; 95% CI, 0.56–0.84).
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
In patients without metastatic disease, resection of the primary tumor, when feasible, is standard practice. In patients with unresectable and/or metastatic cancers, tumor embolization, EBRT, and nephrectomy can aid in the palliation of symptoms caused by the primary tumor or related ectopic hormone or cytokine production.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
In the era before targeted antiangiogenic therapies and immune checkpoint inhibitors, two randomized studies demonstrated an OS benefit in selected patients who underwent initial cytoreductive nephrectomy before the administration of interferon alfa.[5,6] However, there is evidence that undergoing cytoreductive nephrectomy before antiangiogenic therapy does not provide a survival benefit to patients with intermediate- and poor-risk disease. Cytoreductive nephrectomy for good-risk patients has not been studied in a randomized controlled trial in the era of targeted therapies and immunotherapy. The limited data available from retrospective nonrandomized studies suggest a benefit in good-risk patients in the current era of targeted therapies.
The CARMENA trial (NCT00930033) evaluated the effectiveness of cytoreductive nephrectomy before targeted therapy. The study reported no benefit for patients who underwent cytoreductive nephrectomy before receiving treatment with sunitinib, an oral antiangiogenic tyrosine kinase inhibitor.[7] This study enrolled only patients with intermediate- (57%) and poor-risk (43%) disease, whereas a previous retrospective study found that cytoreductive nephrectomy only benefited good- and intermediate-risk patients in the sunitinib era. Similarly, the positive trials in the interferon era were restricted to patients who were asymptomatic or minimally symptomatic, with a performance status rating of 0 or 1, according to the ECOG rating scale; these patients were also considered candidates for postoperative immunotherapy.
A multicenter analysis of 351 patients with metastatic renal cell carcinoma was conducted to assess the impact of cytoreductive nephrectomy. The study evaluated patients who received systemic therapy and compared outcomes of those who underwent cytoreductive nephrectomy with those who did not. The median OS was 38.1 months for patients who underwent nephrectomy compared with 16.4 months for those treated with systemic therapy alone (P = .03). However, the survival benefit was limited to patients with an ECOG performance status rating of 0 to 1 and good- or intermediate-risk disease.[8] Interpretation of the study is limited by selection bias because patients were not randomly assigned to the nephrectomy group. Whether there is a benefit from cytoreductive nephrectomy for patients who are not subsequently treated with systemic therapy has not been tested.
Sources: 8
Randomized controlled trials of cytoreductive nephrectomy:
A randomized, controlled, noninferiority trial of 450 patients compared the outcomes of patients who received sunitinib alone with those who received cytoreductive nephrectomy followed by sunitinib. The trial was designed to enroll 576 individuals; therefore it was underpowered.[7] In this study, 43% of the patients had poor-risk disease and 57% had intermediate-risk disease.
Sources: 7
With a median follow-up of 50.9 months, and after 326 deaths, the HRdeath was 0.89 (95% CI, 0.71–1.10) in favor of sunitinib alone. The median OS was 18.4 months in the sunitinib-alone arm and 13.9 months in the nephrectomy-followed-by-sunitinib arm, but the difference was not statistically significant.[7][Level of evidence A1]
Sources: 7 · Level of evidence A1
Randomized controlled trials of interferon with or without preceding cytoreductive nephrectomy:
Two randomized studies demonstrated an OS benefit in selected patients who underwent initial cytoreductive nephrectomy before the administration of interferon alfa.[5,6]
In the larger study, 246 patients were randomly assigned to either undergo a nephrectomy followed by interferon alfa or receive interferon alfa alone.[5]
Sources: 5
In the larger study, 246 patients were randomly assigned to either undergo a nephrectomy followed by interferon alfa or receive interferon alfa alone.[5]
The median OS was 11.1 months when the primary tumor was removed first (95% CI, 9.2–16.5), compared with 8.1 months in the control arm (95% CI, 5.4–9.5; P = .05).
In the smaller study, 85 patients with identical eligibility criteria were randomly assigned to treatment as in the larger study.[6]
Sources: 6
In the smaller study, 85 patients with identical eligibility criteria were randomly assigned to treatment as in the larger study.[6]
Patients who underwent nephrectomy before receiving interferon alfa had a median OS of 17 months compared with an OS of 7 months in patients who received interferon alfa alone (HR, 0.54; 95% CI, 0.31–0.94; P = .03).[6][Level of evidence A1]
Sources: 6 · Level of evidence A1
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Selected patients with solitary or a limited number of distant metastases can achieve prolonged survival with nephrectomy and surgical resection of the metastases.[48-53] Even patients with brain metastases had similar results.[54] The likelihood of achieving therapeutic benefit with this approach appears enhanced in patients with a long disease-free interval between the initial nephrectomy and the development of metastatic disease.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
A growing understanding of the biology of cancer in general, and renal cell cancer in particular, has led to the development and U.S. Food and Drug Administration (FDA) approval of six new agents that target specific growth pathways. Two of the approved targeted therapies block the mammalian target of rapamycin (mTOR), a serine/threonine protein kinase that regulates cell growth, division, and survival.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Based on research showing that most clear cell renal cell carcinomas carried a variant resulting in constitutive production of cytokines stimulating angiogenesis, several agents that targeted VEGF-mediated pathways were developed. Several of these agents have been shown in randomized, controlled trials to significantly delay progression of clear cell renal cell carcinoma, but none has resulted in a statistically significant increase in OS as conventionally assessed. Many of these trials allowed crossover upon progression and, in some instances, other agents with similar biological activity were available to patients after they withdrew from the clinical trial. These circumstances may have made it more difficult to detect an OS benefit. For the clinician, this makes it challenging to determine the real benefit of these drugs to the patient. The four FDA-approved anti-VEGF agents include three oral TKIs: pazopanib, sorafenib, and sunitinib; and an anti-VEGF monoclonal antibody, bevacizumab. Axitinib is a newer, highly selective, and more potent inhibitor of VEGF receptors 1, 2, and 3. The FDA approved axitinib for the treatment of advanced renal cell carcinoma after the failure of one previously received systemic therapy.[55]
Sources: 55
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Cabozantinib is an oral TKI of the MET, AXL, and VEGF receptors. After a phase I trial showed activity against renal cell carcinoma, a phase III trial assessed the activity of cabozantinib in the second-line setting in a randomized controlled trial.
Evidence (cabozantinib):
The METEOR trial (NCT01865747) randomly assigned 658 patients who had previously been treated with a VEGF TKI to receive either cabozantinib (60 mg qd) or everolimus (10 mg qd).[24,56] Doses were reduced in 60% of the patients receiving cabozantinib, compared with 25% of the patients assigned to everolimus.
The METEOR trial (NCT01865747) randomly assigned 658 patients who had previously been treated with a VEGF TKI to receive either cabozantinib (60 mg qd) or everolimus (10 mg qd).[24,56] Doses were reduced in 60% of the patients receiving cabozantinib, compared with 25% of the patients assigned to everolimus.
The incidence of grade 3 or 4 adverse events was 68% with cabozantinib compared with 58% with everolimus.
The most common high-grade adverse events were hypertension (15%), diarrhea (11%), and fatigue (9%) with cabozantinib, compared with anemia (16%), fatigue (7%), and hyperglycemia (5%) with everolimus.
Dose reductions of cabozantinib were mainly the result of diarrhea, palmar-plantar erythrodysesthesia syndrome, and fatigue.
With a median follow-up of about 19 months, median OS was 21.4 months for patients who received cabozantinib and 16.5 months for patients who received everolimus (HR, 0.66; 95% CI, 0.53–0.83; P = .0003).
These results were confirmed when the prespecified final analysis was performed after 430 deaths had been confirmed. Median survival was 21.4 months with cabozantinib and 17.1 months with everolimus (HR, 0.70; 95% CI, 0.58–0.85).[57]
Sources: 57
A subsequent trial compared cabozantinib with sunitinib in the first-line setting. The study randomly assigned 157 patients with intermediate- or poor-risk metastatic renal cell carcinoma to receive either cabozantinib or sunitinib.[9,10]
A subsequent trial compared cabozantinib with sunitinib in the first-line setting. The study randomly assigned 157 patients with intermediate- or poor-risk metastatic renal cell carcinoma to receive either cabozantinib or sunitinib.[9,10]
Adverse events were seen in more than 95% of the patients.
A subsequent trial compared cabozantinib with sunitinib in the first-line setting. The study randomly assigned 157 patients with intermediate- or poor-risk metastatic renal cell carcinoma to receive either cabozantinib or sunitinib.[9,10] › Adverse events were seen in more than 95% of the patients.
Grade 3 to 4 adverse events were seen in 68% of the patients on the cabozantinib arm and 65% of the patients on the sunitinib arm.
Adverse events included hypertension, diarrhea, fatigue, and thrombocytopenia.
Grade 5 adverse events occurred in 4% of the patients on the cabozantinib arm and 10% of the patients on the sunitinib arm.
A subsequent trial compared cabozantinib with sunitinib in the first-line setting. The study randomly assigned 157 patients with intermediate- or poor-risk metastatic renal cell carcinoma to receive either cabozantinib or sunitinib.[9,10]
With a median follow-up of 34.5 months, there was no significant difference in OS between the two arms, and the OS curves crossed multiple times.
PFS, however, was longer with cabozantinib (8.6 months vs. 5.3 months [HR, 0.48; 95% CI, 0.31–0.74]), demonstrating that PFS is an inadequate surrogate for OS.[9,10][Level of evidence B1]
Sources: 9 · 10 · Level of evidence B1
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Sunitinib and the combination of bevacizumab plus interferon alfa have each been associated with longer PFS than interferon alfa alone in randomized, controlled trials. Sunitinib is an orally available multikinase inhibitor (VEGFR-1, VEGFR-2, PDGFR, c-Kit).
Evidence (sunitinib):
In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]
In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]
Sunitinib as first-line systemic therapy was associated with a median PFS of 11 months, compared with 5 months for interferon alfa.
The HR for progression was 0.42 (95% CI, 0.32–0.54; P < .001).[12][Level of evidence B1]
Sources: 12 · Level of evidence B1
However, the analysis for OS showed a strong but statistically nonsignificant trend to improved survival (26.4 months vs. 21.8 months; HR, 0.82; 95% CI, 0.669–1.001; P = .051).[13][Level of evidence B1]
Sources: 13 · Level of evidence B1
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Pazopanib is an orally available multikinase inhibitor (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, and c-KIT) and has also been approved for the treatment of patients with advanced renal cell carcinoma.
Evidence (pazopanib):
Pazopanib was evaluated in a randomized, placebo-controlled, international trial (VEG015192 [NCT00334282]) that enrolled 435 patients with clear cell or predominantly clear cell renal cell carcinoma.[28] Nearly 50% of the patients had previously received cytokine therapy, although the remainder of them were treatment naïve.
Pazopanib was evaluated in a randomized, placebo-controlled, international trial (VEG015192 [NCT00334282]) that enrolled 435 patients with clear cell or predominantly clear cell renal cell carcinoma.[28] Nearly 50% of the patients had previously received cytokine therapy, although the remainder of them were treatment naïve.
PFS was significantly prolonged in the pazopanib arm at 9.2 months compared with 4.2 months in the placebo arm.
The HR for progression was 0.46 (95% CI, 0.34–0.62; P < .0001), and the median duration of response was longer than 1 year.
Pazopanib was also compared with sunitinib in a randomized controlled trial (NCT00720941) that enrolled 1,110 patients who had metastatic renal cell carcinoma with a clear cell component in a 1:1 ratio.[14] The primary end point was PFS. The study was powered to assess the noninferiority of pazopanib. Results were reported when there was disease progression in 336 of 557 patients (60%) who received pazopanib and in 323 of 553 patients (58%) who received sunitinib.
Sources: NCT00720941 · 14
Pazopanib was also compared with sunitinib in a randomized controlled trial (NCT00720941) that enrolled 1,110 patients who had metastatic renal cell carcinoma with a clear cell component in a 1:1 ratio.[14] The primary end point was PFS. The study was powered to assess the noninferiority of pazopanib. Results were reported when there was disease progression in 336 of 557 patients (60%) who received pazopanib and in 323 of 553 patients (58%) who received sunitinib.
The median PFS was 8.4 months for those in the pazopanib arm and 9.5 months for those in the sunitinib arm (HR, 1.05; CI, 0.9–1.22).
There was no difference in OS (HR, 0.91; 95% CI, 0.76–1.08).
Although QOL was compared in the study, differences in the scheduled administration of the medications made this comparison difficult to interpret.
A subsequent double-blind, randomized, controlled, crossover trial compared sunitinib followed by pazopanib with pazopanib followed by sunitinib. The primary end point was patient preference for one drug over the other.[15] Patients were treated for 10 weeks with either sunitinib or pazopanib, followed by a 2-week washout period, followed by 10 more weeks of treatment with the other drug. Preference was assessed at the end of the second 10-week treatment period. This study design created possible bias in favor of pazopanib.Although the typical regimen for administering sunitinib is a 6-week cycle of 4 weeks on the drug and 2 weeks off the drug, the Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (PISCES [NCT01064310]) chose a treatment period of 10 weeks rather than 12 weeks. Because of this treatment-period change, the 10 weeks of sunitinib treatment included 4 weeks on the drug, followed by 2 weeks off the drug, followed by 4 more weeks on the drug. Patients assigned to pazopanib followed by sunitinib had their preference for treatment assessed at the end of the second 4-weeks-on-the-drug period during which they took sunitinib daily for 28 days. At that point, the sunitinib side effects became the most severe. The expected result from an assessment conducted at the end of a 6-week treatment cycle versus the 4-week treatment cycle would be greatly abated side effects.In addition, the 2-week washout period that occurred between the two 10-week treatment periods was a true break from treatment for patients assigned to take pazopanib first; however, for the patients taking sunitinib, the 2-week washout period was just the completion of their second 6-week treatment cycle. In other words, patients assigned to pazopanib first had a true 2-week break from treatment, and their drug preference was assessed at the peak period of toxic effects from sunitinib; however, the patients assigned to sunitinib first had no true treatment break before starting pazopanib and may have had less opportunity to recover from the side effects of sunitinib.
A subsequent double-blind, randomized, controlled, crossover trial compared sunitinib followed by pazopanib with pazopanib followed by sunitinib. The primary end point was patient preference for one drug over the other.[15] Patients were treated for 10 weeks with either sunitinib or pazopanib, followed by a 2-week washout period, followed by 10 more weeks of treatment with the other drug. Preference was assessed at the end of the second 10-week treatment period. This study design created possible bias in favor of pazopanib.Although the typical regimen for administering sunitinib is a 6-week cycle of 4 weeks on the drug and 2 weeks off the drug, the Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (PISCES [NCT01064310]) chose a treatment period of 10 weeks rather than 12 weeks. Because of this treatment-period change, the 10 weeks of sunitinib treatment included 4 weeks on the drug, followed by 2 weeks off the drug, followed by 4 more weeks on the drug. Patients assigned to pazopanib followed by sunitinib had their preference for treatment assessed at the end of the second 4-weeks-on-the-drug period during which they took sunitinib daily for 28 days. At that point, the sunitinib side effects became the most severe. The expected result from an assessment conducted at the end of a 6-week treatment cycle versus the 4-week treatment cycle would be greatly abated side effects.In addition, the 2-week washout period that occurred between the two 10-week treatment periods was a true break from treatment for patients assigned to take pazopanib first; however, for the patients taking sunitinib, the 2-week washout period was just the completion of their second 6-week treatment cycle. In other words, patients assigned to pazopanib first had a true 2-week break from treatment, and their drug preference was assessed at the peak period of toxic effects from sunitinib; however, the patients assigned to sunitinib first had no true treatment break before starting pazopanib and may have had less opportunity to recover from the side effects of sunitinib.
Despite these limitations, 70% of the patients preferred pazopanib, and 22% of the patients preferred sunitinib (P < .001).
More patients preferred pazopanib regardless of the treatment they received first; however, that difference was greater for the patients who received pazopanib first (80% vs. 11%) compared with the patients who received sunitinib first (62% vs. 32%).
The main side effects cited by the patients that contributed to patient preference were diarrhea, HRQOL, fatigue, loss of appetite, taste changes, nausea and vomiting, hand and foot soreness, stomach pain, and mouth and throat soreness.
The patients who preferred pazopanib cited less fatigue and better overall QOL as the most common reasons for their preference.
The patients who preferred sunitinib cited less diarrhea and better QOL as the most common reasons for their preference.
Physician preference was a secondary end point of the study, and 61% of physicians preferred to continue patient treatment with pazopanib, compared with 22% of physicians who preferred to continue patient treatment with sunitinib.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Sorafenib is an orally available multikinase inhibitor (CRAF, BRAF, KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFRB) and has also been approved for the treatment of patients with advanced renal cell carcinoma.[58]
Sources: 58
Evidence (sorafenib):
In an international, multicenter, randomized trial, 769 patients were stratified by the Memorial Sloan Kettering Cancer Center prognostic risk category and by country. Patients were randomly assigned to receive either sorafenib (400 mg bid) or a placebo. Approximately 82% of the patients had received IL-2 previously and/or interferon alfa in both arms of the study. The primary end points were PFS and OS.
In an international, multicenter, randomized trial, 769 patients were stratified by the Memorial Sloan Kettering Cancer Center prognostic risk category and by country. Patients were randomly assigned to receive either sorafenib (400 mg bid) or a placebo. Approximately 82% of the patients had received IL-2 previously and/or interferon alfa in both arms of the study. The primary end points were PFS and OS.
The median PFS for patients randomly assigned to sorafenib was 167 days compared with 84 days for patients randomly assigned to placebo (P < .001).
The estimated HR for the risk of progression with sorafenib compared with a placebo was 0.44 (95% CI, 0.35–0.55). There was no significant difference in OS.[58][Level of evidence B1]
Sources: 58 · Level of evidence B1
A phase II study randomly assigned 189 patients to either sorafenib or interferon alfa.[29]
Sources: 29
A phase II study randomly assigned 189 patients to either sorafenib or interferon alfa.[29]
No difference was reported in PFS (5.7 months vs. 5.6 months), but sorafenib was associated with better QOL than interferon alfa.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Axitinib has prolonged PFS when given as second-line systemic therapy.
Evidence (axitinib):
A randomized controlled trial of 723 patients conducted at 175 sites in 22 countries evaluated axitinib versus sorafenib as treatment for renal cell carcinoma. Patients had disease with a clear cell component that had progressed during or after first-line treatment with sunitinib (54%), cytokines (35%), bevacizumab plus interferon alfa (8%), or temsirolimus (3%).[36,55] The primary end point was PFS, and the data were analyzed when disease in 88% of the axitinib patients and 90% of the sorafenib patients had progressed, while 58% and 59%, respectively, had died. Comparing the toxicity of the axitinib and sorafenib regimens is complicated because the axitinib arm included a dose-escalation component, and only those patients who tolerated the lower dose were subsequently given the higher doses. Hypertension, nausea, dysphonia, and hypothyroidism were more common with axitinib, whereas palmar-plantar erythrodysesthesia, alopecia, and rash were more common with sorafenib.[36,55]
A randomized controlled trial of 723 patients conducted at 175 sites in 22 countries evaluated axitinib versus sorafenib as treatment for renal cell carcinoma. Patients had disease with a clear cell component that had progressed during or after first-line treatment with sunitinib (54%), cytokines (35%), bevacizumab plus interferon alfa (8%), or temsirolimus (3%).[36,55] The primary end point was PFS, and the data were analyzed when disease in 88% of the axitinib patients and 90% of the sorafenib patients had progressed, while 58% and 59%, respectively, had died. Comparing the toxicity of the axitinib and sorafenib regimens is complicated because the axitinib arm included a dose-escalation component, and only those patients who tolerated the lower dose were subsequently given the higher doses. Hypertension, nausea, dysphonia, and hypothyroidism were more common with axitinib, whereas palmar-plantar erythrodysesthesia, alopecia, and rash were more common with sorafenib.[36,55]
Median PFS was 8.3 months for axitinib and 5.7 months for sorafenib (HRprogression or death, 0.656; 95% CI, 0.552–0.779, one-sided log-rank P < .0001 and a threshold of P < .025 for significance).
Median OS was 20.1 months with axitinib compared with 19.2 months with sorafenib (HR, 0.969; 95% CI, 0.80–1.17, P = .374).
However, the largest benefit was seen in patients who received cytokines as first-line therapy and whose median PFS was 12.2 months with axitinib compared with 8.2 months with sorafenib (P < .0001), while median OS was 29.4 months with axitinib compared with 27.8 months with sorafenib (HR, 0.81; 95% CI, 0.55–1.19; P = .144).
In contrast, in patients who had previously received sunitinib, axitinib was associated with a 2.1-month increase in PFS compared with sorafenib (6.5 months vs. 4.4 months, one-sided P = .002), but median OS was nearly identical: 15.2 months with axitinib compared with 16.5 months with sorafenib (HR, 1.0; 95% CI, 0.782–1.270; P = .49).[36]
Sources: 36
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Tivozanib is a TKI that is selective for the VEGF receptor. A phase III randomized controlled trial compared tivozanib with sorafenib for first-line treatment of patients with metastatic renal cell cancer. The study reported that tivozanib was associated with a longer median PFS, but OS favored sorafenib.[26] A subsequent phase III randomized controlled trial compared the two drugs in patients who had at least two prior systemic treatments, including at least one prior VEGF inhibitor. This second trial reported a longer median PFS for patients treated with tivozanib and no difference in OS.[27] In the United States, the FDA has approved tivozanib for patients who have had two or more prior systemic therapies.
Sources: 26 · 27 · FDA has approved
Evidence (tivozanib):
In an open-label, phase III, randomized controlled trial, tivozanib was compared with sorafenib as initial targeted therapy. The study included 517 patients with metastatic renal cell cancer with a clear cell component who had received zero to one prior systemic therapy. Prior treatment with VEGF-targeted therapy and mTOR inhibitors was not permitted. The primary end point was PFS.[26]
Sources: 26
In an open-label, phase III, randomized controlled trial, tivozanib was compared with sorafenib as initial targeted therapy. The study included 517 patients with metastatic renal cell cancer with a clear cell component who had received zero to one prior systemic therapy. Prior treatment with VEGF-targeted therapy and mTOR inhibitors was not permitted. The primary end point was PFS.[26]
The median PFS was longer for patients who received tivozanib than for patients who received sorafenib (11.9 months vs. 9.1 months; HR, 0.797; 95% CI, 0.639–0.993; P = .042). A total of 156 patients (61%) who had disease progression while receiving sorafenib crossed over to receive tivozanib.[26][Level of evidence B1]
Sources: 26 · Level of evidence B1
There was no difference in OS.
The two medications had different toxicity profiles. Adverse events that were more common with tivozanib than with sorafenib included hypertension (44% vs. 34%) and dysphonia (21% vs. 5%). Adverse events that were more common with sorafenib than with tivozanib included hand-foot skin reaction (54% vs. 14%) and diarrhea (33% vs. 23%).
In an open-label randomized controlled trial (NCT02627963), tivozanib was compared with sorafenib. The study included 350 patients with metastatic renal cell cancer who had previously been treated with at least two different systemic therapies, including one VEGF inhibitor.[27]
Sources: NCT02627963 · 27
In an open-label randomized controlled trial (NCT02627963), tivozanib was compared with sorafenib. The study included 350 patients with metastatic renal cell cancer who had previously been treated with at least two different systemic therapies, including one VEGF inhibitor.[27]
With a median follow-up of 19.0 months, the median PFS was longer for patients who received tivozanib (5.6 months vs. 3.9 months; HR, 0.73; 95% CI, 0.56–0.94; P = .016).[27][Level of evidence B1]
Sources: 27 · Level of evidence B1
No significant difference was reported for OS. The median OS was 16.4 months for patients who received tivozanib and 19.2 months for patients who received sorafenib (HR, 0.97; 95% CI, 0.75–1.24).[59]
Sources: 59
Grades 3 to 4 treatment-related adverse events were reported in 11% of patients who received tivozanib and 10% of patients who received sorafenib.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Temsirolimus is an intravenously administered mTOR inhibitor.
Evidence (temsirolimus):
A phase III randomized controlled trial enrolled intermediate- and poor-risk patients with a variety of subtypes of renal cell carcinoma. The trial was not restricted to clear cell kidney cancer.
A phase III randomized controlled trial enrolled intermediate- and poor-risk patients with a variety of subtypes of renal cell carcinoma. The trial was not restricted to clear cell kidney cancer.
Temsirolimus was shown to result in prolonged OS compared with interferon alfa.
The HRdeath was 0.73 (95% CI, 0.58–0.92; P = .008), making temsirolimus the only therapy for renal cell carcinoma to clearly show results in longer OS than did interferon alfa using conventional statistical analysis.[31]
Sources: 31
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Everolimus is an orally administered mTOR inhibitor.
Evidence (everolimus):
Everolimus was evaluated in a double-blind, randomized, placebo-controlled, phase III trial that enrolled patients with metastatic renal cell carcinoma with a clear cell component that had progressed during or within 6 months of stopping treatment with sunitinib, sorafenib, or both drugs.
Everolimus was evaluated in a double-blind, randomized, placebo-controlled, phase III trial that enrolled patients with metastatic renal cell carcinoma with a clear cell component that had progressed during or within 6 months of stopping treatment with sunitinib, sorafenib, or both drugs.
Median PFS was 4.0 months with everolimus compared with 1.9 months with placebo.[37]
Sources: 37
No difference in OS was reported.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Belzutifan is an HIF-2alpha inhibitor used to treat advanced clear cell renal cell carcinoma in patients with disease progression after one to three prior lines of systemic therapy, including immune checkpoint inhibitors and VEGF-targeted treatments.
The open-label phase III LITESPARK-005 trial (NCT04195750) compared belzutifan with everolimus in patients with advanced clear cell renal cell carcinoma who experienced disease progression after one to three lines of prior systemic therapies, including immune checkpoint inhibitors and VEGF-targeted treatments. The co-primary end points of the study were PFS, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 via blinded independent central review, and OS.[25]The FDA approved belzutifan for the treatment of advanced renal cell carcinoma in the second-line and beyond based on the PFS benefit observed in the trial. However, the trial did not meet the co-primary end point of OS. Also, the cost of belzutifan is $31,000 per month for uninsured patients, while everolimus, a generic drug, costs approximately $450 per month (in 2024 dollars).
Sources: LITESPARK-005 · 25
The open-label phase III LITESPARK-005 trial (NCT04195750) compared belzutifan with everolimus in patients with advanced clear cell renal cell carcinoma who experienced disease progression after one to three lines of prior systemic therapies, including immune checkpoint inhibitors and VEGF-targeted treatments. The co-primary end points of the study were PFS, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 via blinded independent central review, and OS.[25]The FDA approved belzutifan for the treatment of advanced renal cell carcinoma in the second-line and beyond based on the PFS benefit observed in the trial. However, the trial did not meet the co-primary end point of OS. Also, the cost of belzutifan is $31,000 per month for uninsured patients, while everolimus, a generic drug, costs approximately $450 per month (in 2024 dollars).
The trial demonstrated a significant improvement in PFS with belzutifan compared with everolimus (HR, 0.75; 95% CI, 0.63–0.90; P = .0016). Objective response rates were also 19.2% higher in the belzutifan arm (95% CI, 14.8%–24.0%). However, OS did not improve significantly (HR, 0.88; 95% CI, 0.73–1.07; P = .20), indicating no clinically meaningful survival difference. The lack of OS benefit raises concerns about the clinical meaningfulness of the PFS improvement.[25][Level of evidence B1]
Sources: 25 · Level of evidence B1
Grade 3 or higher adverse events of any cause occurred in 61.8% of patients in the belzutifan group (grade 5 severity occurred in 3.5% of patients) and in 62.5% of patients in the everolimus group (grade 5 severity occurred in 5.3% of patients). Adverse events led to treatment discontinuation in 5.9% of patients in the belzutifan group and 14.7% of patients in the everolimus group.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Lenvatinib is a multitargeted tyrosine kinase inhibitor with activity against VEGFR-1, VEGFR-2, and VEGFR-3, with inhibitory activity against fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4), PDGFRA, RET, and KIT.
Evidence (lenvatinib plus everolimus):
The combination of lenvatinib plus everolimus was compared with each medication as a single agent in a randomized, controlled phase II study of 153 subjects with advanced-stage renal cell carcinoma who had received previous antiangiogenic therapy.[23] The primary end point was PFS.
Sources: 23
The combination of lenvatinib plus everolimus was compared with each medication as a single agent in a randomized, controlled phase II study of 153 subjects with advanced-stage renal cell carcinoma who had received previous antiangiogenic therapy.[23] The primary end point was PFS.
Median PFS was significantly longer in the combination arm (14.6 months) than in the everolimus arm (5.5 months) (HR, 0.40; 95% CI, 0.24–0.68).[23][Level of evidence B1]
Sources: 23 · Level of evidence B1
Median PFS was 7.4 months for lenvatinib, which was not significantly shorter than in the combination arm (HR, 0.66; 0.39–1.10), but was significantly longer than in the everolimus arm (HR, 0.61; 95% CI, 0.38–0.98; P = .048).
There was no significant difference in OS at the time of data cutoff. A later, post hoc analysis of OS with longer follow-up did show longer survival in the combination arm compared with the everolimus-alone arm (25.5 months [95% CI, 16.4 to not evaluable] vs. 15.4 months [95% CI, 11.8–19.6]; HR, 0.51; 95% CI, 0.30–0.88; P = .024).
Median OS in the lenvatinib-alone arm was 19.1 months and did not differ significantly from the other two arms.
All patients experienced adverse events and almost all of these were judged to be related to treatment. Seventy-one percent of patients had adverse events that were grade 3 or higher. The most common toxicities in the combination arm were diarrhea, hypertension, fatigue, loss of appetite, vomiting, and cough. One patient in the combination arm died of a cerebral hemorrhage that was thought to be related to treatment.
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Responses to cytotoxic chemotherapy generally have not exceeded 10% for any regimen that has been studied in adequate numbers of patients.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on:
the stage of the disease
your age and general health
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Recurrent renal cell cancer is cancer that has come back after it has been treated. If renal cell cancer comes back, it may come back in the kidney or in other parts of the body. Tests will be done to help determine where the cancer has returned. The type of treatment for recurrent renal cell cancer will depend on where it has come back.
Learn more in Recurrent Cancer: When Cancer Comes Back.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
There are different types of treatment for people with renal cell cancer.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy
Immunotherapy
Targeted therapy
New types of treatment are being tested in clinical trials.
Treatment for renal cell cancer may cause side effects.
Follow-up care may be needed.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Different types of treatments are available for people with renal cell cancer. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. To learn more, see Questions to Ask Your Doctor About Treatment.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Surgery to remove part or all of the kidney is often used to treat renal cell cancer. The following types of surgery may be used:
Partial nephrectomy is surgery to remove the cancer within the kidney and some of the tissue around it. A partial nephrectomy may be done to prevent loss of kidney function when the other kidney is damaged or has already been removed.
Sources: kidney function
Simple nephrectomy is surgery to remove the kidney only.
Radical nephrectomy is surgery to remove the kidney, the adrenal gland, surrounding tissue, and usually nearby lymph nodes.
Sources: adrenal gland · lymph nodes
A person can live with part of one working kidney, but if both kidneys are removed or not working, the person will need dialysis (a procedure to clean the blood using a machine outside of the body) or a kidney transplant (replacement with a healthy donated kidney). A kidney transplant may be done when the disease is in the kidney only and a donated kidney can be found. If the person has to wait for a donated kidney, other treatment is given as needed.
After the doctor removes all the cancer that can be seen at the time of the surgery, some people may receive radiation therapy to kill any cancer cells that are left. Treatment given after surgery to lower the risk that the cancer will come back is called adjuvant therapy.
Sources: adjuvant therapy
When surgery to remove the cancer is not possible, other procedures might be done:
Arterial embolization may be used to shrink the tumor. A small incision (cut) is made, and a catheter (thin tube) is inserted into the main blood vessel that flows to the kidney. Small pieces of a special gelatin sponge are injected through the catheter into the blood vessel. The sponges block the blood flow to the kidney and prevent the cancer cells from getting oxygen and other substances they need to grow.
Sources: Arterial embolization · blood vessel · injected
Cryosurgery uses an instrument to freeze and destroy abnormal tissue. This type of treatment is also called cryotherapy. Learn more about Cryosurgery to Treat Cancer.
Sources: Cryosurgery to Treat Cancer
Thermal ablation (also called hyperthermia) uses heat to destroy abnormal tissue. Learn more about Hyperthermia to Treat Cancer.
Sources: Hyperthermia to Treat Cancer
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External beam radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. External beam radiation therapy is used to treat renal cell cancer, and may also be used as palliative therapy to relieve symptoms and improve quality of life. A specific way to give radiation therapy called stereotactic ablative body radiation therapy, or stereotactic radiosurgery, may be used in some cases.
Sources: External beam radiation therapy · palliative therapy · quality of life · stereotactic ablative body radiation therapy
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Immunotherapy helps a person's immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Immunotherapy drugs used to treat renal cell cancer include:
avelumab
Sources: avelumab
interferon
Sources: interferon
interleukin-2
Sources: interleukin-2
ipilimumab
Sources: ipilimumab
nivolumab
Sources: nivolumab
pembrolizumab
Sources: pembrolizumab
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
Targeted therapies used to treat renal cell cancer include:
axitinib
Sources: axitinib
bevacizumab
Sources: bevacizumab
cabozantinib
Sources: cabozantinib
everolimus
Sources: everolimus
lenvatinib
Sources: lenvatinib
pazopanib
Sources: pazopanib
sorafenib
Sources: sorafenib
sunitinib
Sources: sunitinib
temsirolimus
Sources: temsirolimus
tivozanib
Sources: tivozanib
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
After treatment for renal cell cancer, a blood test to measure amounts of carcinoembryonic antigen (a substance in the blood that may be increased when cancer is present) may be done to see if the cancer has come back.
Sources: blood test · carcinoembryonic antigen
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The main treatment for stage I renal cell cancer is surgery:
Sources: stage I renal cell cancer
partial nephrectomy
Sources: partial nephrectomy
simple nephrectomy
Sources: simple nephrectomy
radical nephrectomy
Sources: radical nephrectomy
If surgery isn't an option, treatment options may include:
cryotherapy
Sources: cryotherapy
thermal ablation
Sources: thermal ablation
stereotactic ablative body radiation therapy (a type of external beam radiation therapy)
If none of these treatments is an option, palliative therapy aimed at relieving symptoms may include:
Sources: palliative therapy
external beam radiation therapy
Sources: external beam radiation therapy
arterial embolization
Sources: arterial embolization
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of stage II renal cell cancer may include:
Sources: stage II renal cell cancer
partial nephrectomy
Sources: partial nephrectomy
radical nephrectomy
Sources: radical nephrectomy
radical nephrectomy followed by pembrolizumab, for cancer that is at high risk of coming back
Sources: pembrolizumab
nephrectomy before or after external beam radiation therapy
Sources: nephrectomy · external beam radiation therapy
external beam radiation therapy or arterial embolization as palliative therapy to relieve symptoms, if surgery isn't an option
Sources: arterial embolization · palliative therapy
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of stage III renal cell cancer may include:
Sources: stage III renal cell cancer
radical nephrectomy
Sources: radical nephrectomy
arterial embolization to reduce blood loss during surgery followed by radical nephrectomy
Sources: arterial embolization
radical nephrectomy followed by pembrolizumab or sunitinib
Sources: pembrolizumab · sunitinib
external beam radiation therapy or arterial embolization as palliative therapy to relieve symptoms and improve the quality of life
Sources: external beam radiation therapy · palliative therapy · symptoms
external beam radiation therapy before or after surgery (radical nephrectomy), for certain people with more extensive tumors
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Renal Cell Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
First-line treatment of stage IV renal cell cancer may include:
Sources: First-line treatment · stage IV renal cell cancer
ipilimumab plus nivolumab
Sources: ipilimumab · nivolumab
pembrolizumab plus axitinib
Sources: pembrolizumab · axitinib
pembrolizumab plus lenvatinib
Sources: lenvatinib
nivolumab plus cabozantinib
Sources: cabozantinib
radical nephrectomy
Sources: radical nephrectomy
nephrectomy to reduce the size of the tumor in people with certain favorable tumor types
Sources: nephrectomy
cabozanitnib
avelumab plus axitinib
Sources: avelumab
sunitinib
Sources: sunitinib
pazopanib
Sources: pazopanib
sorafenib
Sources: sorafenib
temsirolimus
Sources: temsirolimus
bevacizumab with or without interferon
Sources: bevacizumab · interferon
interferon
interleukin-2
Sources: interleukin-2
palliative radiation therapy
Sources: palliative · radiation therapy
Second-line treatment may include:
Sources: Second-line treatment
nivolumab (for people previously treated with sunitinib, pazopanib, sorafenib, and/or axitinib)
lenvatinib plus everolimus (for people previously treated with sunitinib, pazopanib, cabozantinib, axitinib, or sorafenib)
Sources: everolimus
cabozantinib (for people previously treated with sunitinib, pazopanib, sorafenib, or axitinib)
axitinib
everolimus (for people previously treated with sunitinib and/or sorafenib)
sorafenib
palliative radiation therapy
Third-line and fourth-line treatment may include:
Sources: Third-line
tivozanib for people who have had at least two other types of systemic treatments
any of the treatments listed for first-line or second-line therapy
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Carcinoma, Renal Cell
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordKidney Neoplasms
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordMetastatic Renal Cell Carcinoma
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordRenal Cell Cancer
ClinicalTrials.gov recordMetastatic Renal Cell Carcinoma
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordMetastatic Renal Cell Carcinoma
ClinicalTrials.gov recordAdvanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
ClinicalTrials.gov recordClear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordAdvanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordRenal Cell Cancer
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordVHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation, VHL-Associated Renal Cell Carcinoma, VHL-Associated Clear Cell Renal Cell Carcinoma
ClinicalTrials.gov recordMetastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, TFE3-Rearranged Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordRenal Cell Carcinoma
ClinicalTrials.gov recordClear Cell Renal Cell Carcinoma
ClinicalTrials.gov recordCarcinoma, Renal Cell
ClinicalTrials.gov recordKidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
ClinicalTrials.gov recordKidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
ClinicalTrials.gov recordKidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
ClinicalTrials.gov recordNeuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ...
ClinicalTrials.gov recordBreast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
ClinicalTrials.gov record1.3 Renal Cell Carcinoma (RCC) AFINITOR is indicated for the treatment of adult patients with advanced RCC after failure of treatment with sunitinib or sorafenib.
1.4 Metastatic Renal Cell Carcinoma Alymsys, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
1.4 Metastatic Renal Cell Carcinoma Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC.
1.1 Renal Cell Carcinoma CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
• in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.
• as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
1.4 Metastatic Renal Cell Carcinoma Jobevne, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
1.14 Renal Cell Carcinoma KEYTRUDA QLEX, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
1.16 Renal Cell Carcinoma KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.
1.4 Metastatic Renal Cell Carcinoma MVASI, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous...
• OPDIVO, as a single agent, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
1 INDICATIONS AND USAGE Proleukin is a lymphocyte growth factor indicated for: The treatment of adults with metastatic renal cell carcinoma.
Renal Cell Cancer
Treatment of Stage I Renal Cell Cancer
Treatment of Stage II Renal Cell Cancer
Treatment of Stage III Renal Cell Cancer
Treatment of Stage IV and Recurrent Renal Cell Cancer
Treatment Options for First-Line Therapy for Stage IV Renal Cell Cancer
Advanced renal cell carcinoma
1.3 Adjuvant Treatment of Renal Cell Carcinoma SUTENT is indicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.
1.4 Metastatic Renal Cell Carcinoma VEGZELMA, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
1 INDICATIONS AND USAGE VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC).
1.2 Renal Cell Carcinoma with a Clear Cell Component (ccRCC) WELIREG, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the adjuvant treatment of adult patients with ccRCC at...
• Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab.
1.4 Metastatic Renal Cell Carcinoma ZIRABEV, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
CABOMETYX is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab ( 1.1 )...
DailyMed labelFOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is a kinase inhibitor indicated for the treatment of adult...
DailyMed labelINLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of...
DailyMed labelINLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of...
DailyMed labelLENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer...
DailyMed labelOPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate...
DailyMed labelProleukin is a lymphocyte growth factor indicated for: The treatment of adults with metastatic renal cell carcinoma. ( 1.1 ) The treatment of adults with metastatic melanoma. ( 1.2 ) 1.1 Metastatic Renal Cell Carcinoma Proleukin is...
DailyMed labelSUTENT is a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced...
DailyMed labelTORISEL is indicated for the treatment of advanced renal cell carcinoma. TORISEL ® is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. ( 1 )
DailyMed labelWELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central...
DailyMed label